RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock UpZacks Investment Research • 02/25/26
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/25/26
What's in Store for These 5 Medical Companies This Earnings Season?Zacks Investment Research • 02/23/26
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25GlobeNewsWire • 02/18/26
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 02/04/26
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 01/29/26
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference TranscriptSeeking Alpha • 01/22/26
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025Seeking Alpha • 12/18/25
Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP TranscriptSeeking Alpha • 12/08/25
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 WeeksGlobeNewsWire • 12/08/25
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/25